Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

Operational Update and Bioanalysis Commencement

• Onco-Innovations announced that Nucro-Technics Inc. has commenced advanced bioanalytical work for its PNKP Inhibitor Technology (A83B4C63).
• The study focuses on non-GLP pharmacokinetic (PK) and biodistribution animal model studies to prepare for IND-enabling plans.
• This is a critical step in transitioning the technology from early-stage discovery toward a development-ready therapeutic candidate.

Stock Price Reaction and Sentiment

• The stock closed at $0.38 on the news date (May 8, 2026), down from $0.40 the previous day, indicating a negative market reaction to operational progress.
• Despite positive operational milestones, the market continues to price in significant dilution risk and capital structure concerns.

Core Business Model

• Onco-Innovations focuses on developing next-generation DNA Damage Response Inhibitor (DDRi) therapies targeting PTEN/SHP1-deficient cancers.
• The company operates through a subsidiary structure including Inka Health Corp for AI-driven evidence generation and SynoGraph technology.